Aesthetics manufacturer Croma-Pharma has entered a licensing agreement with dermatology company Crescita Therapeutics for the rights to Pliaglis.

Pliaglis is a topical local anaesthetic cream which aims to provide safe and effective dermal analgesia on intact skin prior to procedures such as dermal filler, facial laser resurfacing and pulsed dye laser therapy, explains Crescita Therapeutics.

Croma-Pharma explain that it will promote Pliaglis directly to practitioners through its sale network consisting of 130 members across the nine countries, including Germany, UK, Ireland, Switzerland, Brazil, Romania, Belgium, the Netherlands and Luxembourg. Crescita will be the sole supplier of Pliaglis under the agreement at a price per unit including a profit margin, whilst Croma-Pharma expects to launch Pliaglis to most of these countries throughout 2022.

Croma-Pharma managing director, Andreas Prinz, commented, “We are looking forward to collaborating with Crescita on Pliaglis which complements our portfolio of aesthetic injectable products, right at a time when we are about to enter the market of pharmaceuticals. We are delighted to launch Pliaglis in some of our most important markets where it will certainly become an important pillar within Croma’s product family.”